Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331658 | 0.90 | CYP2C19 (0.52) | ESR1ESR2CNR2CNR1LMNA | |
| SCHEMBL628354 | 0.78 | MAOB (0.47) | ESR1ESR2CNR2CNR1ALDH1A1 | |
| SCHEMBL3065138 | 0.74 | TSHR (0.63) | CNR2ALDH1A1LMNACYP2C19SLC6A3 | |
| SCHEMBL3339451 | 0.72 | PYCR1 (0.58) | ESR1ESR2ALDH1A1LMNAPYCR1 | |
| SCHEMBL9709954 | 0.72 | CHRM2 (0.50) | ALDH1A1LMNACYP2C19SLC6A2SLC6A4 | |
| SCHEMBL3737073 | 0.71 | KCNJ1 (0.51) | ALDH1A1PYCR1LOXL2 | |
| SCHEMBL11206092 | 0.71 | CNR2 (0.51) | ESR1ESR2CNR2CNR1BCL2A1 | |
| SCHEMBL7047352 | 0.70 | ESR1 (0.57) | ESR1ESR2BCL2A1ALDH1A1PYCR1 | |
| SCHEMBL22340467 | 0.70 | CNR2 (0.51) | CNR2CNR1ALDH1A1LMNA | |
| SCHEMBL933733 | 0.70 | ESR1 (0.57) | ESR1ESR2BCL2A1ALDH1A1PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1436077-A | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2003-08-13 | — | — | CN | claimed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | claimed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | claimed |
| US-20100144696-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144697-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| CN-100450483-C | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2009-01-14 | — | — | CN | disclosed |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| CN-1436077-A | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2003-08-13 | — | — | CN | disclosed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144696-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | ESR1 3949/4885ESR2 4716/4885CNR2 204/4885 |
| US-20100144697-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | ESR1 3949/4885ESR2 4716/4885CNR2 204/4885 |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | ESR1 3949/4885ESR2 4716/4885CNR2 204/4885 |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1S, CACNA1C, CACNA1D | ESR1 4554/4885ESR2 4662/4885CNR2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.